Mr Shafi has embarked on an Executive MBA (EMBA) at Cambridge University. This is a major commitment and will support his national Medical Director role with Nuffield Health. The EMBA will take around 20 months. The studies will take place at the Judge Business School in Cambridge on a part time basis.
The U.S. Food and Drug Administration has approved Gardasil 9 Human Papillomavirus (HPV) vaccine to include women and men aged 27 through 45 years. Gardasil 9 prevents certain cancers and diseases caused by the nine HPV types covered by the vaccine. HPV vaccination prior to becoming infected with the HPV types covered by the vaccine has the potential to prevent more than 90 percent of these cancers. This is a major step forward in reducing the burden associated with HPV associated conditions particularly the relevant cancers in women and men. HPV vaccination is now well established in the United Kingdom and it is hoped that this will aid in widening the coverage and effect of this programme. In the UK, previously only girls were eligible for the vaccine but this will change to include boys. The vaccine will be delivered at age 12-13 so that it becomes a ‘gender neutral’ programme.
There has been wide media coverage of the use of mesh for stress urinary incontinence. Following a review, there are restrictions on their usage and a period of high vigilance is recommended. This particularly applied to Tension-free Vaginal Tapes (TVT). There is now a national review taking place of the safety of these procedures and we anticipate that further guidance will be provided in 2019. The National Institute for Health and Clinical Excellence will undertake the review.